Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
ActivBiotics |
---|---|
Information provided by: | ActivBiotics |
ClinicalTrials.gov Identifier: | NCT00251849 |
The objective of this study is to determine whether rifalazil can significantly increase peak walking time (PWT) in patients with peripheral arterial disease (PAD).
Condition | Intervention | Phase |
---|---|---|
Peripheral Vascular Diseases Intermittent Claudication |
Drug: Rifalazil |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Prospective Evaluation of Rifalazil Effect On Vascular Symptoms of Intermittent Claudication and Other Endpoints in Chlamydia Seropositive Patients |
Estimated Enrollment: | 274 |
Study Start Date: | November 2005 |
Estimated Study Completion Date: | December 2007 |
Ages Eligible for Study: | 40 Years to 80 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ABI-1648-022 |
Study First Received: | November 9, 2005 |
Last Updated: | August 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00251849 |
Health Authority: | United States: Food and Drug Administration |
Intermittent Claudication |
Arterial Occlusive Diseases Signs and Symptoms Peripheral Vascular Diseases Chlamydia Infections Vascular Diseases |
Intermittent Claudication Arteriosclerosis KRM 1648 Pneumonia |
Anti-Infective Agents Anti-Bacterial Agents Therapeutic Uses Cardiovascular Diseases |
Antitubercular Agents Pharmacologic Actions Leprostatic Agents Antibiotics, Antitubercular |